Journal article icon

Journal article

A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer

Abstract:
Background In the current study, the authors sought to determine the maximum tolerated dose (MTD) of the novel class 1 selective histone deacetylase inhibitor CXD101 in a dose escalation study in patients with advanced solid tumors or recurrent/refractory lymphoma.

Methods The authors escalated the dose of CXD101 from 1 mg twice daily orally for 5 days in a 21‐day cycle (3+3 design).

Results A total of 39 patients were e... Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1002/cncr.31791

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Role:
Author
ORCID:
0000-0002-8803-4234
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Role:
Author
Publisher:
Wiley
Journal:
Cancer More from this journal
Volume:
125
Issue:
1
Pages:
99-108
Publication date:
2018-10-17
Acceptance date:
2018-08-24
DOI:
EISSN:
1097-0142
ISSN:
0008-543X
Pmid:
30332497
Language:
English
Keywords:
Pubs id:
pubs:929733
UUID:
uuid:c83dcd5f-9a5e-4435-971e-36f833bcf4a2
Local pid:
pubs:929733
Source identifiers:
929733
Deposit date:
2019-06-24

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP